Department of Health and Human Services October 6, 2006 – Federal Register Recent Federal Regulation Documents

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), announces that the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in United States Patent Application Number 60/ 181,909 entitled ``Identification of a Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function'' filed February 11, 2000 (HHS Ref. No. E-095- 2000/0-US-01); U.S. Patent Application No. PCT/US01/04125 entitled ``Identification of a Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function'' filed February 9, 2001, 2000 (HHS Ref. No. E-095-2000/0-PCT- 02); U.S. Patent Application No. 10/203,495, filed August 9, 2002, entitled ``Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function'' (E- 095-2000/0-US-03); U.S. Patent Application No. 60/694,015 entitled ``Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors'' filed June 24, 2005 [E-095-2000/2-US-01]; U.S. Patent Application No. 60/717,589 entitled ``Amelioration of Inflammatory Arthritis Targeting the Pre- ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors'' filed September 16, 2005 [E-095-2000/3-US-01]; U.S. PCT Application entitled ``A Potential Novel Therapeutic Protein Molecule of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptor Type 1'' filed February 9, 2001 [E- 095-2000/4-PCT-01]; European Patent Application No. 01910476.9 entitled ``Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function'' filed February 9, 2001 [E-095-2000/0-EP-06]; Australian Patent Application No. 2001238076 entitled ``Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function'' issued on February 9, 2001 [E-095-2000/0-AU- 04]; and Canadian Patent Application No. 2399388 entitled ``Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function'' filed February 9, 2001, [E-095-2000/0-CA-05] to Domantis, Inc. The prospective exclusive license territory may be worldwide and the field of use may be limited to therapeutic applications for autoimmune diseases including rheumatoid arthritis (RA) inflammatory bowel disease (IBD) and psoriasis as covered under the agreement and based upon the Patent Rights.